在淋巴瘤和多发性骨髓瘤中缓解时间毒性
Mengyang Di1,2,3, Christopher T Su2,3, Andrew J Cowan1,2
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Leukemia & lymphoma
|May 15, 2024
概括
在非霍奇金淋巴瘤和多发性骨髓瘤中检查时间毒性,影响患者福祉的频繁医疗保健访问. 讨论了减少时间毒性的策略,以改善患者护理和治疗决策.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 患者为中心的护理
背景情况:
- 瘤学中的时间毒性描述了影响患者福祉的负担重重的医疗保健相互作用.
- 频繁的预约和治疗计划可以显著影响患有血液性恶性瘤的患者.
研究的目的:
- 审查非霍奇金淋巴瘤和多发性骨髓瘤中时间毒性的表现.
- 讨论时间毒性对临床决策和治疗选择的影响.
- 探索在淋巴瘤和骨髓瘤治疗中减轻时间毒性的策略.
主要方法:
- 文献综述研究了非霍奇金淋巴瘤和多发性骨髓瘤的时间毒性.
- 分析时间毒性如何影响治疗选择 (例如,化疗免疫疗法与向药物).
- 在新疗法 (如CAR T细胞和双特异性抗体) 的背景下讨论时间毒性.
主要成果:
- 时间毒性会影响治疗选择,例如在毛囊性淋巴瘤中,化疗免疫疗法与lenalidomide-rituximab对比.
- 骨髓瘤中蛋白酶体抑制剂和双酸盐的最佳剂量计划是由时间毒性决定的.
- 化学抗原受体T细胞疗法和双特异抗体表现出不同的时间毒性概况.
结论:
- 时间毒性是淋巴瘤和髓瘤患者护理的关键因素,影响治疗决策.
- 测量时间毒性作为试验终点具有挑战性,但对于以患者为中心的护理至关重要.
- 现有策略可以减少治疗的时间毒性,而不会影响疗效或安全.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


